Finanzwire Finanzwire
Basculer en Français
10022 Companies
203534 Keywords
133976 Articles
107997 Press releases
Headlines Articles Press releases Revive Therapeutics Ltd. Remove
  1. Home
  2. Companies
  3. Revive Therapeutics Ltd.
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 03/11/2026 at 12:35, 3 hours 48 minutes ago

    Revive Therapeutics Expands Bucillamine's Patent Portfolio in North America

    Patent Portfolio Infectious Diseases Bucillamine Nerve Agent Revive Therapeutics
  • PRESS RELEASE

    published on 03/11/2026 at 12:30, 3 hours 53 minutes ago

    Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

    Revive Therapeutics announces key patent milestones for Bucillamine in medical countermeasures and infectious diseases, strengthening its strategic position
    Medical Countermeasures Infectious Diseases Bucillamine Revive Therapeutics Patent Milestones
    Logo of Revive Therapeutics Ltd.
Accesswire
  • Published on 03/11/2026 at 15:55, 28 minutes ago

    Caledonia Mining Corporation Plc Notice of Q4 and FY 2025 Results and Investor Presentation

  • Published on 03/11/2026 at 14:27, 1 hour 56 minutes ago

    Faraday Copper Announces Closing of C$100 Million Offering with Participation by a Lundin Family Trust and BHP

  • Published on 03/11/2026 at 14:00, 2 hours 23 minutes ago

    Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

  • Published on 03/11/2026 at 13:30, 2 hours 53 minutes ago

    NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

  • Published on 03/11/2026 at 13:00, 3 hours 23 minutes ago

    GameSquare Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

View all ACCESSWIRE
EQS Group
  • Published on 03/11/2026 at 15:43, 39 minutes ago

    audius significantly exceeds 2025 annual targets / dynamic growth of 29% predominantly organic / very strong operating cash flow

  • Published on 03/11/2026 at 15:35, 48 minutes ago

    The Games of the Future 2026: Dates and Disciplines Confirmed for Astana

  • Published on 03/11/2026 at 15:05, 1 hour 18 minutes ago

    Dometic Launches Modular Drinkware: One System. Built to Adapt. Any way. Anywhere.

  • Published on 03/11/2026 at 15:05, 1 hour 18 minutes ago

    From Concept to Mass Production: Risen Energy's Journey with Ultra-Thin Wafers

  • Published on 03/11/2026 at 14:19, 2 hours 4 minutes ago

    Algo Grande announces new, high-grade copper discovery!

View all EQS
Les Echos
  • Published on 03/11/2026 at 08:00, 8 hours 22 minutes ago

    BIOPHYTIS ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT

  • Published on 03/11/2026 at 07:00, 9 hours 23 minutes ago

    TINC publishes excellent results with a record investment year as the basis for future profit growth

  • Published on 03/10/2026 at 17:45, 22 hours 38 minutes ago

    Number of outstanding shares and voting rights as of 28 February 2026

  • Published on 03/10/2026 at 17:45, 22 hours 38 minutes ago

    OPmobility reshapes its Executive Committee to further adapt to market needs and accelerate the execution of its strategy

  • Published on 03/10/2026 at 17:39, 22 hours 44 minutes ago

    Haulotte - 2025 Annual Results

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy